CD163 and neoplasm: Recently, in resected stage I-IIIA NSCLC patients [8] we demonstrated densities of tumour-associated CD66+ neutrophils and CD163+ macrophages were correlated with adverse clinical prognostic factors as well as CRP and white blood cell (WBC) systemic inflammatory markers.